# StapleBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/staplebio-co

- Industry: Pharmaceuticals
- Headquarters: Kumamoto, Japan
- Website: https://staplebio.jp
- Total disclosed funding: $3M
- Latest round: Series A (Apr 1, 2024)
- Investors on record: 5

## About

Founded in 2021 and based in Kumamoto, Japan, StapleBio Co., Ltd. operates as a pharmaceutical company that develops drugs. The company was founded by its CEO, Kiyoshi Tanigawa, and CSO, Yosuke Katsuta. In April 2024, StapleBio Inc. raised JPY 460 million in Series A funding led by Diamond Medino Capital, Mitsubishi UFJ Capital, and Summit Pharmaceuticals International Corporation.

StapleBio develops pharmaceuticals with the help of its next-generation nucleic acid medicine technology. The firm’s product line includes Staple nucleic acids, a next-generation nucleic acid drug technology that can target specific RNA molecules linked to diseases and alter their structure, which can regulate protein production, potentially offering a treatment for various diseases.

The company plans to use the funds raised in April 2024 to hire more researchers, expand its research facility, develop its drug discovery platform, and add more to its pipeline.

## Funding rounds

- Series A, Apr 1, 2024, $3M — Mitsubishi UFJ Capital, Higin Capital, Diamond Medino Capital, Taiho Innovations, LLC., Summit Pharmaceuticals International Corporation

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Higin Capital (https://capitalatlas.ai/funds/higin-capital) — Series A
- Diamond Medino Capital (https://capitalatlas.ai/funds/diamond-medino-capital) — Series A
- Taiho Innovations, LLC. — Series A
- Summit Pharmaceuticals International Corporation — Series A